Innovative lipids for Your Nucleic Acid Delivery research

The history and evolution of Nucleic Acid Delivery systems

mRNA and liposomes were both first discovered in the 1960s, and liposomes were used to deliver mRNA into eukaryotic cells in 1978.1,2 Even with the ability to inject mRNA into cells, there were several technical challenges to overcome before mRNA could be used as a therapeutic, primarily the rapid degradation of mRNA once injected into the body. In 1990, naked mRNA was injected into the muscles of rats to prove that in vivo direct gene transfer was possible.3 As early as 1995 the first mRNA vaccine carrying cancer antigens was reported.4 And more recently, lipid nanoparticles (LNPs) have been used to deliver mRNA capable of fighting SARS-CoV-2, as well as CRISPR/Cas-9 gene editing technologies.

Our understanding of mRNA and its delivery has evolved substantially in the past few decades – from naked mRNA delivery to liposomal delivery and then LNPs. We are far from where we started and probably equally as far away, if not farther, from where we are headed.

Not only do delivery systems change, but their individual components are constantly evolving to meet current challenges and demands. To date, LNPs have primarily been formulated using the following components:

Recent research has been directed at finding new, innovative ways to improve encapsulation and transfection efficiency, and stability, as well as reduce systemic toxicity of LNP therapeutics. Keep reading to see how LNP components are evolving and where LNP technology is headed!

Considerations for future cationic lipids

In LNP formulations, cationic ionizable lipids are used to complex negatively charged mRNA. Aside from playing a major role in the LNP formulation itself, cationic lipids also serve a major role in the biological administration of mRNA to target cells. The RNA-loaded LNP fuses with the cell membrane and is then delivered into the cytosol. To be able to play these roles efficiently, a cationic ionizable lipid must be engineered with a suitable apparent acid dissociation constant (pKa). The apparent pKa of a cationic ionizable lipid is the likely pKa at the LNP surface. Currently, the cationic ionizable lipids in FDA-approved therapeutics all have an apparent pKa between 6-7. This is crucial for the cationic ionizable lipid to maintain a neutral charge while in systemic circulation (pH above the pKa of the lipid, pH ~7.5), as well as its ability to become positively charged in the endosome (pH ~6.5) and facilitate membrane fusion and subsequent cytosolic release.⁵

As crucial components in LNPs, new cationic ionizable lipids for nucleic acid delivery are being investigated to optimize mRNA complexation, endosomal membrane fusion and cargo release into the cytosol. Stay up to date on Avanti’s cationic lipid offerings here.

PEGylated lipids and the future of stealth agents in LNPs

Historically, polyethylene glycol (PEG)-lipids have been the polymer-lipid conjugate of choice for LNP formulations. PEG-lipids are used to prevent proteins from binding to LNPs and increase systemic circulation times, mediate indirect targeting capabilities of LNPs, promote LNP self-assembly, and control LNP size and stability. The ability of LNPs formulated with PEG-lipids to bypass the reticulo-endothelial clearance system and stay in systemic circulation gives them their nickname – “stealth agents”.⁵

As great as PEG-lipids are, they also present a few challenges. These challenges are commonly referred to as the “PEG dilemma”:⁶

Steric hindrance of long PEG chains hinders the ability of a cell to uptake the therapeutic

PEGylation also hinders endosomal escape of nanoparticles, leading to decreased activity of the delivery system

Repeated administration of PEGylated systems can result in a phenomenon called accelerated blood clearance (ABC)

Other alternatives to PEG-lipids in LNPs are being explored, and recent work has identified polysarcosine (pSar)-lipids as a promising alternative. pSar-lipids, a polymer-lipid conjugate based on the amino acid sarcosine, have demonstrated similar stealth properties to PEG-lipids. Previous studies have also shown polysarcosine lipids to induce a lower immunogenic response than PEG-lipids when administered to rabbits, zebrafish embryos, and mice. And most recently, pSar-lipids were evaluated in mRNA-LNPs and displayed high RNA transfection ability and an improved safety profile.⁷ Avanti is now offering pSar-lipids with varying polymeric chain lengths and lipid chain lengths for your PEG-free mRNA delivery research!

Read the full Croda article

Source: Croda https://www.crodapharma.com/en-gb/news-and-blog/innovative-lipids-for-your-nucleic-acid-delivery-research

Author: Kyle Black,Technical Marketing Lead, Avanti Polar Lipids